IDXX — IDEXX Laboratories, Inc.

Is IDXX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of November 17, 2026

IDEXX Laboratories, Inc. (IDXX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $700.65. The rating moved from Neutral to Overbought on November 10, 2026.

See all overbought Healthcare stocks →

AI analysis

IDEXX Laboratories, Inc. (IDXX) combines a defensible diagnostics franchise with high-margin recurring consumables and attractive cash generation. Near-term catalysts include continued adoption of new assays/instruments, international expansion and bolt-on M&A that can extend addressable markets. Financial health is characterized by consistent revenue growth and healthy operating cash flow, supporting reinvestment and shareholder-return optionality. Key challenges include demand sensitivity to broader economic conditions, competitive assay/platform pressure, and execution risks around product rollout and supply chains. Under plausible scenarios, steady execution and sustained consumable growth support mid-single-digit to high-single-digit percentage upside over the next month, while pronounced macro weakness or significant competitive disruption could compress volumes and margins.

Key factors

  • Leading market share in veterinary diagnostics and point-of-care instruments with recurring consumables revenue (tests and reagents) supporting predictable revenue streams
  • Strong historical revenue and free cash flow generation enabling organic investment and targeted M&A to extend product portfolio and international reach
  • High margin business mix driven by diagnostics consumables and software/services, offering resilience to near-term top-line variability
  • Favorable structural tailwinds: growing pet ownership, higher spend per pet, and increased preventative/professional veterinary care penetration globally
  • Product cycle and attach-rate upside from new instrument installs and adoption of next‑generation assays
  • Defensive healthcare/diagnostics positioning in a risk-on market window, with investor flows into defensive healthcare exposures supporting relative outperformance

Risks

  • Near-term demand sensitivity if consumer discretionary spending on pet care contracts during macro or recessionary pressure
  • Competition from large diagnostics and animal-health players, including competing assays, point-of-care platforms, or lower-cost alternatives
  • Execution risk on new product launches or international expansion; slower instrument installs would reduce consumable growth
  • Supply-chain, manufacturing or reagent/kit shortages that could constrain sales and margins
  • Currency exposure and foreign-market reimbursement/regulatory changes that could weigh on reported results
  • Possible margin pressure from pricing competition or increased investment needs (R&D, commercialization) to sustain growth

See today's live rating, score and targets

Members see the live hourly rating for IDXX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.